Remifentanil for Sedation of Patients With Traumatic Brain Injury (TBI)
- Registration Number
- NCT02049320
- Lead Sponsor
- Joseph D. Tobias
- Brief Summary
This is a descriptive retrospective study designed to measure the efficacy of remifentanil sedation and the ability to perform frequent neurological examinations of patients with traumatic brain injuries.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
- Patients previously admitted to the hospital presenting with traumatic brain injury (TBI)
- Patients who have undergone sedation after presenting with TBI
Exclusion Criteria
- None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Remifentanil Remifentanil Patients sedated using Remifentanil
- Primary Outcome Measures
Name Time Method Depth of Sedation Every 24 hrs until discharged from the PICU, up to 1 month. Sedation scores will be assessed.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which remifentanil affects neurological assessments in TBI patients?
How does remifentanil sedation compare to propofol in TBI patients regarding neurological exam frequency?
Are there specific biomarkers that correlate with remifentanil efficacy in traumatic brain injury management?
What adverse events are associated with remifentanil use in TBI patients and how are they managed?
What combination therapies with remifentanil show promise in improving outcomes for moderate to severe TBI?
Trial Locations
- Locations (1)
Nationwide Children's Hospital
🇺🇸Columbus, Ohio, United States
Nationwide Children's Hospital🇺🇸Columbus, Ohio, United States